ICU - SeaStar Medical Holding Corporation Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ICU

SEASTAR MEDICAL HOLDING CORPORATION

NASDAQ

$3.09

▼ DOWN 0.32% (-0.01)

KEY STATISTICS

Market Cap$8.77 M

52w High$12.50

52w Low$2.07

Dividend Yield—

Frequency—

P/E-0.97

Volume17.09K

Shares Out.2.84M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Eric Schlorff

COMPENSATION 2026

Salary$406,500

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$406,500

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 18, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$8.00

Target Low$8.00

Target Median$8.00

Target Consensus$8.00

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$500.00K

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2026-01-05	Reverse	1:10
2024-06-10	Reverse	1:25

PRICE

$3.09 ▼ DOWN 0.32% (−$0.01)

OVERLAYS

About SeaStar Medical Holding Corporation

https://www.seastarmedical.com ↗

SeaStar Medical develops extracorporeal therapies to treat hyperinflammation and cytokine storms in critically ill patients across conditions like acute kidney injury, cardiorenal syndrome, and hepatorenal syndrome.

INDUSTRY

Biotechnology

A PRODUCT SEASTAR MEDICAL HOLDING CORPORATION IS KNOWN FOR

QUELIMMUNE

QUELIMMUNE's FDA-approved Selective Cytopheretic Device (SCD) therapy treats pediatric AKI caused by sepsis by neutralizing overactive immune cells and reducing hyperinflammation.